Eunice Kennedy Shriver National Institutes of Child Health and Human Development, Bethesda, Maryland.
Department of Oncology, Pediatric Blood and Marrow Transplantation Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland.
Ann Am Thorac Soc. 2021 Mar;18(3):381-394. doi: 10.1513/AnnalsATS.202001-006OT.
Approximately 2,500 pediatric hematopoietic cell transplants (HCTs), most of which are allogeneic, are performed annually in the United States for life-threatening malignant and nonmalignant conditions. Although HCT is undertaken with curative intent, post-HCT complications limit successful outcomes, with pulmonary dysfunction representing the leading cause of nonrelapse mortality. To better understand, predict, prevent, and/or treat pulmonary complications after HCT, a multidisciplinary group of 33 experts met in a 2-day National Institutes of Health Workshop to identify knowledge gaps and research strategies most likely to improve outcomes. This summary of Workshop deliberations outlines the consensus focus areas for future research.
每年，美国大约要进行 2500 例儿科造血细胞移植（HCT），其中大多数为异基因 HCT，用于治疗危及生命的恶性和非恶性疾病。尽管 HCT 是带着治愈的目的进行的，但移植后的并发症限制了成功的结果，肺部功能障碍是导致非复发死亡的主要原因。为了更好地理解、预测、预防和/或治疗 HCT 后的肺部并发症，一个由 33 名专家组成的多学科小组在为期两天的美国国立卫生研究院研讨会上会面，以确定最有可能改善结果的知识空白和研究策略。本研讨会审议摘要概述了未来研究的共识重点领域。
